Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation

Charlotte King; Amanda McKenna; Niloufar Farzan; Susanne J. Vijverberg; Marc P. van der Schee; Anke H. Maitland-van der Zee; Lambang Arianto; Hans Bisgaard; Klaus BØnnelykke; Vojko Berce; Uroš Potočnik; Katja Repnik; Bruce Carleton; Denise Daley; Fook Tim Chew; Wen Chin Chiang; Yang Yie Sio; Michelle M. Cloutier; Herman T. Den Dekker; Liesbeth Duijts; Johan C. de Jongste; F. Nicole Dijk; Gerard H. Koppelman; Carlos Flores; Natalia Hernandez-Pacheco; Maria Pino-Yanes; Somnath Mukhopadhyay; Kaninika Basu; Lauren Bignell; Kelan G. Tantisira; Steve Turner; Katia M. Verhamme; Ben Francis; Munir Pirmohamed; Ian Sinha; Daniel B. Hawcutt

doi:10.1038/s41397-019-0140-y

Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation

Charlotte King, Amanda McKenna, Niloufar Farzan, Susanne J. Vijverberg, Marc P. van der Schee, Anke H. Maitland-van der Zee, Lambang Arianto, Hans Bisgaard, Klaus BØnnelykke, Vojko Berce, Uroš Potočnik, Katja Repnik, Bruce Carleton, Denise Daley, Fook Tim Chew, Wen Chin Chiang, Yang Yie Sio, Michelle M. Cloutier, Herman T. Den Dekker, Liesbeth DuijtsJohan C. de Jongste, F. Nicole Dijk, Gerard H. Koppelman, Carlos Flores, Natalia Hernandez-Pacheco, Maria Pino-Yanes, Somnath Mukhopadhyay, Kaninika Basu, Lauren Bignell, Kelan G. Tantisira, Steve Turner, Katia M. Verhamme, Ben Francis, Munir Pirmohamed, Ian Sinha, Daniel B. Hawcutt^* (Corresponding Author)

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

7 Citations (Scopus)

6 Downloads (Pure)

Abstract

A systematic review of pharmacogenomic studies capturing adverse drug reactions (ADRs) related to asthma medications was undertaken, and a survey of Pharmacogenomics in Childhood Asthma (PiCA) consortia members was conducted. Studies were eligible if genetic polymorphisms were compared with suspected ADR(s) in a patient with asthma, as either a primary or secondary outcome. Five studies met the inclusion criteria. The ADRs and polymorphisms identified were change in lung function tests (rs1042713), adrenal suppression (rs591118), and decreased bone mineral density (rs6461639) and accretion (rs9896933, rs2074439). Two of these polymorphisms were replicated within the paper, but none had external replication. Priorities from PiCA consortia members (representing 15 institution in eight countries) for future studies were tachycardia (SABA/LABA), adrenal suppression/crisis and growth suppression (corticosteroids), sleep/behaviour disturbances (leukotriene receptor antagonists), and nausea and vomiting (theophylline). Future pharmacogenomic studies in asthma should collect relevant ADR data as well as markers of efficacy.

Original language	English
Pages (from-to)	621-628
Number of pages	8
Journal	Pharmacogenomics Journal
Volume	20
Early online date	17 Jan 2020
DOIs	https://doi.org/10.1038/s41397-019-0140-y
Publication status	Published - Oct 2020

Bibliographical note

We would like to thank the NIHR Collaboration for Leadership in Applied Health Research and Care North West Coast (CLAHRC) for funding Amanda McKenna’s internship, and Charlotte Kings MPhil, and the members of the PiCA consortia for their help in completing the survey. U. Potočnik, K. Repnik and V. Berce were supported by SysPharmPedia grant, co-financed by Ministry of Education, Science and Sport of the Republic of Slovenia

Author information
These authors contributed equally: Charlotte King, Amanda McKenna
These authors jointly supervised this work: Ian Sinha, Daniel B. Hawcutt

Keywords

CHILDREN
EXACERBATIONS
RISK
POLYMORPHISM
BURDEN

Access to Document

10.1038/s41397-019-0140-yLicence: CC BY

King_etal_PJ_Phrmacogenomic_VOR
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Final published version, 843 KBLicence: CC BY

Cite this

King, C., McKenna, A., Farzan, N., Vijverberg, S. J., van der Schee, M. P., Maitland-van der Zee, A. H., Arianto, L., Bisgaard, H., BØnnelykke, K., Berce, V., Potočnik, U., Repnik, K., Carleton, B., Daley, D., Chew, F. T., Chiang, W. C., Sio, Y. Y., Cloutier, M. M., Den Dekker, H. T., ... Hawcutt, D. B. (2020). Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation. Pharmacogenomics Journal, 20, 621-628. https://doi.org/10.1038/s41397-019-0140-y

King, C, McKenna, A, Farzan, N, Vijverberg, SJ, van der Schee, MP, Maitland-van der Zee, AH, Arianto, L, Bisgaard, H, BØnnelykke, K, Berce, V, Potočnik, U, Repnik, K, Carleton, B, Daley, D, Chew, FT, Chiang, WC, Sio, YY, Cloutier, MM, Den Dekker, HT, Duijts, L, de Jongste, JC, Dijk, FN, Koppelman, GH, Flores, C, Hernandez-Pacheco, N, Pino-Yanes, M, Mukhopadhyay, S, Basu, K, Bignell, L, Tantisira, KG, Turner, S, Verhamme, KM, Francis, B, Pirmohamed, M, Sinha, I & Hawcutt, DB 2020, 'Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation', Pharmacogenomics Journal, vol. 20, pp. 621-628. https://doi.org/10.1038/s41397-019-0140-y

@article{f57269a2159c441aa11e6d9400880a72,

title = "Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation",

abstract = "A systematic review of pharmacogenomic studies capturing adverse drug reactions (ADRs) related to asthma medications was undertaken, and a survey of Pharmacogenomics in Childhood Asthma (PiCA) consortia members was conducted. Studies were eligible if genetic polymorphisms were compared with suspected ADR(s) in a patient with asthma, as either a primary or secondary outcome. Five studies met the inclusion criteria. The ADRs and polymorphisms identified were change in lung function tests (rs1042713), adrenal suppression (rs591118), and decreased bone mineral density (rs6461639) and accretion (rs9896933, rs2074439). Two of these polymorphisms were replicated within the paper, but none had external replication. Priorities from PiCA consortia members (representing 15 institution in eight countries) for future studies were tachycardia (SABA/LABA), adrenal suppression/crisis and growth suppression (corticosteroids), sleep/behaviour disturbances (leukotriene receptor antagonists), and nausea and vomiting (theophylline). Future pharmacogenomic studies in asthma should collect relevant ADR data as well as markers of efficacy.",

keywords = "CHILDREN, EXACERBATIONS, RISK, POLYMORPHISM, BURDEN",

author = "Charlotte King and Amanda McKenna and Niloufar Farzan and Vijverberg, {Susanne J.} and {van der Schee}, {Marc P.} and {Maitland-van der Zee}, {Anke H.} and Lambang Arianto and Hans Bisgaard and Klaus B{\O}nnelykke and Vojko Berce and Uro{\v s} Poto{\v c}nik and Katja Repnik and Bruce Carleton and Denise Daley and Chew, {Fook Tim} and Chiang, {Wen Chin} and Sio, {Yang Yie} and Cloutier, {Michelle M.} and {Den Dekker}, {Herman T.} and Liesbeth Duijts and {de Jongste}, {Johan C.} and Dijk, {F. Nicole} and Koppelman, {Gerard H.} and Carlos Flores and Natalia Hernandez-Pacheco and Maria Pino-Yanes and Somnath Mukhopadhyay and Kaninika Basu and Lauren Bignell and Tantisira, {Kelan G.} and Steve Turner and Verhamme, {Katia M.} and Ben Francis and Munir Pirmohamed and Ian Sinha and Hawcutt, {Daniel B.}",

note = "We would like to thank the NIHR Collaboration for Leadership in Applied Health Research and Care North West Coast (CLAHRC) for funding Amanda McKenna{\textquoteright}s internship, and Charlotte Kings MPhil, and the members of the PiCA consortia for their help in completing the survey. U. Poto{\v c}nik, K. Repnik and V. Berce were supported by SysPharmPedia grant, co-financed by Ministry of Education, Science and Sport of the Republic of Slovenia Author information These authors contributed equally: Charlotte King, Amanda McKenna These authors jointly supervised this work: Ian Sinha, Daniel B. Hawcutt",

year = "2020",

month = oct,

doi = "10.1038/s41397-019-0140-y",

language = "English",

volume = "20",

pages = "621--628",

journal = "Pharmacogenomics Journal",

issn = "1470-269X",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Pharmacogenomic associations of adverse drug reactions in asthma

T2 - systematic review and research prioritisation

AU - King, Charlotte

AU - McKenna, Amanda

AU - Farzan, Niloufar

AU - Vijverberg, Susanne J.

AU - van der Schee, Marc P.

AU - Maitland-van der Zee, Anke H.

AU - Arianto, Lambang

AU - Bisgaard, Hans

AU - BØnnelykke, Klaus

AU - Berce, Vojko

AU - Potočnik, Uroš

AU - Repnik, Katja

AU - Carleton, Bruce

AU - Daley, Denise

AU - Chew, Fook Tim

AU - Chiang, Wen Chin

AU - Sio, Yang Yie

AU - Cloutier, Michelle M.

AU - Den Dekker, Herman T.

AU - Duijts, Liesbeth

AU - de Jongste, Johan C.

AU - Dijk, F. Nicole

AU - Koppelman, Gerard H.

AU - Flores, Carlos

AU - Hernandez-Pacheco, Natalia

AU - Pino-Yanes, Maria

AU - Mukhopadhyay, Somnath

AU - Basu, Kaninika

AU - Bignell, Lauren

AU - Tantisira, Kelan G.

AU - Turner, Steve

AU - Verhamme, Katia M.

AU - Francis, Ben

AU - Pirmohamed, Munir

AU - Sinha, Ian

AU - Hawcutt, Daniel B.

N1 - We would like to thank the NIHR Collaboration for Leadership in Applied Health Research and Care North West Coast (CLAHRC) for funding Amanda McKenna’s internship, and Charlotte Kings MPhil, and the members of the PiCA consortia for their help in completing the survey. U. Potočnik, K. Repnik and V. Berce were supported by SysPharmPedia grant, co-financed by Ministry of Education, Science and Sport of the Republic of Slovenia Author information These authors contributed equally: Charlotte King, Amanda McKenna These authors jointly supervised this work: Ian Sinha, Daniel B. Hawcutt

PY - 2020/10

Y1 - 2020/10

N2 - A systematic review of pharmacogenomic studies capturing adverse drug reactions (ADRs) related to asthma medications was undertaken, and a survey of Pharmacogenomics in Childhood Asthma (PiCA) consortia members was conducted. Studies were eligible if genetic polymorphisms were compared with suspected ADR(s) in a patient with asthma, as either a primary or secondary outcome. Five studies met the inclusion criteria. The ADRs and polymorphisms identified were change in lung function tests (rs1042713), adrenal suppression (rs591118), and decreased bone mineral density (rs6461639) and accretion (rs9896933, rs2074439). Two of these polymorphisms were replicated within the paper, but none had external replication. Priorities from PiCA consortia members (representing 15 institution in eight countries) for future studies were tachycardia (SABA/LABA), adrenal suppression/crisis and growth suppression (corticosteroids), sleep/behaviour disturbances (leukotriene receptor antagonists), and nausea and vomiting (theophylline). Future pharmacogenomic studies in asthma should collect relevant ADR data as well as markers of efficacy.

AB - A systematic review of pharmacogenomic studies capturing adverse drug reactions (ADRs) related to asthma medications was undertaken, and a survey of Pharmacogenomics in Childhood Asthma (PiCA) consortia members was conducted. Studies were eligible if genetic polymorphisms were compared with suspected ADR(s) in a patient with asthma, as either a primary or secondary outcome. Five studies met the inclusion criteria. The ADRs and polymorphisms identified were change in lung function tests (rs1042713), adrenal suppression (rs591118), and decreased bone mineral density (rs6461639) and accretion (rs9896933, rs2074439). Two of these polymorphisms were replicated within the paper, but none had external replication. Priorities from PiCA consortia members (representing 15 institution in eight countries) for future studies were tachycardia (SABA/LABA), adrenal suppression/crisis and growth suppression (corticosteroids), sleep/behaviour disturbances (leukotriene receptor antagonists), and nausea and vomiting (theophylline). Future pharmacogenomic studies in asthma should collect relevant ADR data as well as markers of efficacy.

KW - CHILDREN

KW - EXACERBATIONS

KW - RISK

KW - POLYMORPHISM

KW - BURDEN

UR - http://www.scopus.com/inward/record.url?scp=85078235110&partnerID=8YFLogxK

U2 - 10.1038/s41397-019-0140-y

DO - 10.1038/s41397-019-0140-y

M3 - Review article

C2 - 31949291

AN - SCOPUS:85078235110

SN - 1470-269X

VL - 20

SP - 621

EP - 628

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

ER -

Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this